RTIL 13RTIL 13
MedChemExpress (MCE)
HY-115739
1009376-10-6
Please store the product under the recommended conditions in the Certificate of Analysis.
Room temperature in continental US
may vary elsewhere.
RTIL 13 is a potent inhibitor of dynamin GTPase, with an IC50 of 2.3 μM for dynamin I GTPase. RTIL 13 also targets pleckstrin homology lipid binding domain. RTIL 13 can inhibit receptor-mediated and synaptic vesicle endocytosis, with IC50s of 9.3 μM and 7.1 μM, respectively.
RTIL 13 inhibits receptor-mediated and synaptic vesicle endocytosis, with IC50s of 9.3 μM and 7.1 μM, respectively[2].
IC50: 2.3 µM (dynamin I GTPase)[1] In Vitro RTIL 13 inhibits receptor-mediated and synaptic vesicle endocytosis, with IC50s of 9.3 μM and 7.1 μM, respectively[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> RTIL 13 Related Antibodies
| | | |
| | | | | |
[1]. Zhang J, et, al. From Spanish fly to room-temperature ionic liquids (RTILs): synthesis, thermal stability and inhibition of dynamin 1 GTPase by a novel class of RTILs. New Journal of Chemistry. 2008 Jan
32(1): 1-180.
[2]. Ascent Scientific Launch Novel Dynamin Inhibitor Dyngo-4a™ with Children's Medical Research Institute and University of Newcastle. Tuesday, December 28, 2021.